Prevalence of BRCA mutations among women with triple-negative breast cancer (TNBC) in a genetic counseling cohort. - Wikidata - wikimedia - TriplyDB

Prevalence of BRCA mutations among women with triple-negative breast cancer (TNBC) in a genetic counseling cohort.

Prevalence of BRCA mutations among women with triple-negative breast cancer (TNBC) in a genetic counseling cohort.

http://www.wikidata.org/entity/Q38131418

about

Surgery in the era of the 'omics revolution Evolution of pre-existing versus acquired resistance to platinum drugs and PARP inhibitors in BRCA-associated cancers Opportunities for improving triple‐negative breast cancer outcomes: results of a population‐based study Challenges in the Treatment of Triple Negative and HER2-Overexpressing Breast Cancer Triple-negative breast cancer in African-American women: disparities versus biology.Inhibition of Cdk2 kinase activity selectively targets the CD44⁺/CD24⁻/Low stem-like subpopulation and restores chemosensitivity of SUM149PT triple-negative breast cancer cells.Effects of age on the detection and management of breast cancer.Increased ID4 expression, accompanied by mutant p53 accumulation and loss of BRCA1/2 proteins in triple-negative breast cancer, adversely affects survival.Inherited predisposition to breast cancer among African American women.Significant clinical impact of recurrent BRCA1 and BRCA2 mutations in Mexico.Clinical and molecular characteristics of triple-negative breast cancer patients in Northern Israel: single center experience What Black Women Know and Want to Know About Counseling and Testing for BRCA1/2 Triple negative breast cancer in North of Morocco: clinicopathologic and prognostic features Breast cancer subtype of French women is not influenced by socioeconomic status: A population-based-study.Metastasis of Pregnancy-Associated Breast Cancer (Suspected to Be Hereditary Breast and Ovarian Cancer) to the Brain, Diagnosed at 18 Weeks' Gestation: A Case Report and Review of the Literature.Mathematical models of breast and ovarian cancers.Attribution to Heterogeneous Risk Factors for Breast Cancer Subtypes Based on Hormone Receptor and Human Epidermal Growth Factor 2 Receptor Expression in Korea.Identification of recurrent BRCA1 mutation and its clinical relevance in Chinese Triple-negative breast cancer cohort.The value of platinum agents as neoadjuvant chemotherapy in triple-negative breast cancers: a systematic review and meta-analysis.Limited family structure and triple-negative breast cancer (TNBC) subtype as predictors of BRCA mutations in a genetic counseling cohort of early-onset sporadic breast cancers.A practice guideline from the American College of Medical Genetics and Genomics and the National Society of Genetic Counselors: referral indications for cancer predisposition assessment.The 2014 Society of Surgical Oncology Susan G. Komen for the Cure Symposium: triple-negative breast cancer.Genomic medicine and risk prediction across the disease spectrum.Disparities in breast cancer and african ancestry: a global perspective.Triple-Negative Breast Cancer in Ghanaian Women: The Korle Bu Teaching Hospital Experience.Next Generation Sequencing Reveals High Prevalence of BRCA1 and BRCA2 Variants of Unknown Significance in Early-Onset Breast Cancer in African American Women.Metabolomics Analysis of Hormone-Responsive and Triple-Negative Breast Cancer Cell Responses to Paclitaxel Identify Key Metabolic Differences.Germline Mutations in Triple-Negative Breast Cancer.Drug-Driven Synthetic Lethality: Bypassing Tumor Cell Genetics with a Combination of AsiDNA and PARP Inhibitors The spectrum of BRCA mutations and characteristics of BRCA-associated breast cancers in China: Screening of 2,991 patients and 1,043 controls by next-generation sequencing.Deleterious BRCA1/2 mutations in an urban population of Black women.Evaluation of Local and Distant Recurrence Patterns in Patients with Triple-Negative Breast Cancer According to Age.Clinical Characteristics in Patients with Triple Negative Breast Cancer.Efficacy and Safety of Vinorelbine Plus Cisplatin vs. Gemcitabine Plus Cisplatin for Treatment of Metastatic Triple-Negative Breast Cancer After Failure with Anthracyclines and Taxanes.Breast Cancer Genetic Testing Among African Patients With Breast Cancer: Deoxyribonucleic Acid Extraction From Tumor Tissue and International Multidisciplinary Partnerships.Obesity and Triple-Negative Breast Cancer: Disparities, Controversies, and Biology.The role of BRCA status on prognosis in patients with triple-negative breast cancer.Comparison of Neoadjuvant Nab-Paclitaxel+Carboplatin vs Nab-Paclitaxel+Gemcitabine in Triple-Negative Breast Cancer: Randomized WSG-ADAPT-TN Trial Results.Germline BRCA1/BRCA2 mutations among high risk breast cancer patients in Jordan.Differences in breast cancer incidence among young women aged 20-49 years by stage and tumor characteristics, age, race, and ethnicity, 2004-2013.

P2860

Q26852061-412E1088-A0D5-4383-8547-33BDE72AE0E4 Q28542563-23ADA292-479A-4DB8-A6C0-C3F6A5381070 Q29248325-D69A8D5A-D4AE-4C2F-9EA4-E1D5B9B4CBE5 Q33576608-4A0EC315-7799-4015-BF3C-F3B4278B7195 Q33797203-56540315-8B6A-42D7-BDA3-6092641BB80D Q34000650-B2A49F86-DE71-4E01-89E0-A9F8FDD0CC82 Q34477879-70ADA375-F9C0-473E-B355-15BF5C524796 Q34489002-EA4C99A2-B1CF-40D0-A7F2-4C6CBB3CC93F Q34983596-02277B8F-014A-47C1-85CB-6F9A08413B79 Q35007651-B7167C1F-A931-44C5-A8DC-3F7072AB6634 Q35214479-6059B27B-0A5F-4F67-A117-454571F457D3 Q35370858-73EC0145-08F8-46D0-9F9B-219908A06DE1 Q36172054-26D4D01B-0EE6-48E7-9D54-7E868106ED47 Q36281065-93F1379A-B281-4C01-BF7D-01B90E654D91 Q36615358-AFE75E12-BC11-4AFD-85E4-1EE0D82097D4 Q37014152-E2F47D95-1D89-4F4F-A9F9-08A0D91F9CBC Q37206557-95B207F3-C765-4193-9E9F-745767AFAEBA Q37693410-BC3A13D9-6BAB-4107-A854-1E87C0A808F5 Q38190005-B795F8A8-3370-42AF-963F-C8E7F9EE7209 Q38262476-6F0BEDED-9715-4B5F-A95E-77A93603BFBC Q38267932-AFF89F3C-C9BB-4D57-A1F2-45D441E04BD0 Q38295108-A1264427-327A-4B10-BE0E-B10A6897B821 Q38322338-2D711600-260A-4526-B143-C7E9791F2DE7 Q38339360-E122806F-D1FD-442C-8A4A-9747B8E474C8 Q38411443-01CC6C0B-E63A-4372-A2E4-DFD0129E32A3 Q38691342-B8D19A5E-352A-4418-8D47-5950262FC8B1 Q38756385-37775F34-449F-4E97-9864-B491F2AD40F7 Q39370774-7B851695-4628-4EFB-BC4C-F2F61A0B41BB Q39455545-680FA38F-7925-4840-BA63-6E9BAE6DF320 Q40292155-E2823FA7-7DFE-4110-B7EC-B41F04E3A43C Q40303275-A6FC79CB-1FD1-43CC-B21B-27B3999B7057 Q40514586-9F76DFA9-47DF-405E-AFCB-CB7EA6F52B77 Q41623076-57536509-53BF-4720-8234-E525AF99915B Q42275833-E2D0E650-9BB0-4DA2-8D31-5808B44588B1 Q46162041-036134D0-F0A5-44D3-98F1-E4EB5C124663 Q46759303-A3808E40-F23C-4246-8C77-9328B4604742 Q47097677-8FB9A1FF-1037-43AF-A80B-A54C03158D14 Q47788774-37F75557-81D5-4176-B914-76E3B6128B5C Q49573714-70F7784E-3743-438A-BAC6-571AF978579E Q49992737-03DC3393-3873-4D34-8A81-36765EE11A11

P2860

Prevalence of BRCA mutations among women with triple-negative breast cancer (TNBC) in a genetic counseling cohort.

http://www.wikidata.org/entity/Q38131418

description

article científic

@ca

article scientifique

@fr

articol științific

@ro

articolo scientifico

@it

artigo científico

@gl

artigo científico

@pt

artigo científico

@pt-br

artikel ilmiah

@id

artikull shkencor

@sq

artículo científico

@es

name

Prevalence of BRCA mutations a ...... n a genetic counseling cohort.

@en

type

label

Prevalence of BRCA mutations a ...... n a genetic counseling cohort.

@en

prefLabel

Prevalence of BRCA mutations a ...... n a genetic counseling cohort.

@en

P1433

Q38131418-A4D1CB9B-7300-4D01-AA5A-F7FCDBA295F8

P1476

Q38131418-6CA30B54-F592-4A38-9761-CE28AD6DA7ED

P2093

Q38131418-1E2B86D9-2657-4D31-B8A4-6A77EF6800CA

Q38131418-2E005DEE-3FAB-4386-9DD1-5652C05ED673

Q38131418-3F78DD83-32E4-4C10-B05C-3C61509434AD

Q38131418-63F4A628-BD5F-4CB0-9598-817CB9FD98DB

Q38131418-84A72CA1-DFB7-4A82-8A28-05CA8DDCED95

Q38131418-976471FC-A835-462F-A6A3-473C5D971F18

Q38131418-C28D732E-F57F-490E-AA04-314F31C427BF

Q38131418-ED09A3F8-BE0A-455D-B4F2-6CADFB15CF77

Q38131418-EDDDBC5A-21B1-4B1E-968D-384C10B12BDB

Q38131418-F0B4EF7F-1113-4C7C-AF42-3582F2FE5AD2

P2860

Q38131418-1DB32FE3-7FE2-436B-8FFB-992355D0BB17

Q38131418-33420689-D3A4-432A-B890-20F7F496295D

Q38131418-804C09FE-1A19-456E-BF7D-79FD97CF7262

Q38131418-B4219D1A-1188-4333-926C-990260A301A4

Q38131418-B771C680-5AE7-4A2E-8FD5-025E1901173D

Q38131418-BB913FC8-AF56-4A85-9F53-C9DB50ADD801

Q38131418-DFFC5D09-B885-4058-BA49-45B254E31ED9

Q38131418-EEA25B3F-3A15-4645-8724-1EE2727C9355

Q38131418-EF270C78-27F6-4F9B-82A0-11718AACCD5D

Q38131418-F8B78A1A-E69E-4911-A65C-CAFDB1CB2254

P2888

Q38131418-F9290BC1-9232-4F17-80D6-E98F2DA99582

P304

Q38131418-7A9D9047-9732-4B68-8582-7E6F98CD7FBF

P31

Q38131418-3E72A999-B881-491A-BD24-9DAF7B4FA95C

P356

Q38131418-90778D17-0394-410F-88C1-C6BFCE5BD638

P433

Q38131418-DCFB7387-7E39-4437-AD62-F19FD00AE070

P478

Q38131418-C5F01B42-D9D7-4233-A9A0-CF6CC60DA5AF

P577

Q38131418-123AEBF7-1F3B-4C60-90EE-33DDEC2D87FD

P6179

Q38131418-4688ADD2-751B-460A-AECE-3DDB4EEEF547

P698

Q38131418-428A2476-E1D0-4767-B016-30CB2256D63E

P356

S10434-013-3205-1

P1433

Annals of Surgical Oncology

P1476

Prevalence of BRCA mutations a ...... n a genetic counseling cohort.

@en

P2093

Adam Buchanan

http://www.w3.org/2001/XMLSchema#string

Beth Crawford

http://www.w3.org/2001/XMLSchema#string

E Shelley Hwang

http://www.w3.org/2001/XMLSchema#string

Jane McLennan

http://www.w3.org/2001/XMLSchema#string

Keelia Rhoads

http://www.w3.org/2001/XMLSchema#string

P Kelly Marcom

http://www.w3.org/2001/XMLSchema#string

Rachel Greenup

http://www.w3.org/2001/XMLSchema#string

Robin King

http://www.w3.org/2001/XMLSchema#string

Salina Chan

http://www.w3.org/2001/XMLSchema#string

Tracey Leedom

http://www.w3.org/2001/XMLSchema#string

P2860

The prevalence of BRCA1 mutations among young women with triple-negative breast cancer.

Incidence and outcome of BRCA mutations in unselected patients with triple receptor-negative breast cancer

American Society of Clinical Oncology policy statement update: genetic testing for cancer susceptibility.

BRCA1 testing should be offered to individuals with triple-negative breast cancer diagnosed below 50 years.

Relative contributions of BRCA1 and BRCA2 mutations to "triple-negative" breast cancer in Ashkenazi Women.

Incorporating tumor immunohistochemical markers in BRCA1 and BRCA2 carrier prediction.

BRCA1 and BRCA2 mutations in women of different ethnicities undergoing testing for hereditary breast-ovarian cancer.

American Society of Clinical Oncology policy statement update: genetic and genomic testing for cancer susceptibility.

Prevalence of BRCA mutations in an unselected population of triple-negative breast cancer.

BRCAPRO validation, sensitivity of genetic testing of BRCA1/BRCA2, and prevalence of other breast cancer susceptibility genes

P2888

s10434-013-3205-1

P304

3254-3258

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1245/S10434-013-3205-1

http://www.w3.org/2001/XMLSchema#string

P433

10

http://www.w3.org/2001/XMLSchema#string

P478

20

http://www.w3.org/2001/XMLSchema#string

P577

2013-08-22T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P6179

1016423735

http://www.w3.org/2001/XMLSchema#string

P698

23975317

http://www.w3.org/2001/XMLSchema#string